Business Wire

CGTN

23.3.2021 20:21:13 CET | Business Wire | Press release

Share
CGTN: Xi's Fujian Tour: Forestry, Healthcare, Rural Revitalization

Forestry reform, reform of the medical and healthcare system, and rural revitalization were highlighted in Chinese President Xi Jinping's second day of his inspection tour in east China's Fujian Province on Tuesday.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005995/en/

Visiting the Shaxian District of Sanming City on Tuesday, Xi went to an assets and equity exchange to learn about local efforts to deepen reform of the forest tenure system and a hospital to learn about local reform of the medical and healthcare system.

He also went to a village to inspect work on promoting rural revitalization.

'Lush mountains and lucid waters are valuable assets'

In the past, Chinese farmers were excluded from collective forestry and shared few timber revenues. As a result, they lacked the incentives to protect forests, and timber theft was rampant.

To solve these problems, Fujian Province launched the reform to decentralize the collective forest tenure system in favor of individual (household) management in 2003, which is also considered the start of China's new round of forest tenure reform.

It echoed Xi's instruction to develop forestry as an industry while maintaining its ecological functions when he worked in Fujian.

Xi had visited Sanming City 11 times when he worked in Fujian. During a trip to the city in June 2002, when he was Fujian governor, Xi emphasized that environmental development was of paramount importance.

He said at the time that it might seem that green mountains and lucid waters are of little value, but in the long term, they are valuable assets. He also urged local officials to transform economic growth and avoid wasting resources and damaging the environment.

To carry out Xi's instructions, local authorities further explored a number of reform measures, including taking steps to encourage farmers to transfer their timberland to forest cooperatives and other operators and issuing more loans to forestry businesses to solve their financial problems.

The total output value of forestry reached 114.6 billion yuan in 2019 in Sanming. The city's forest coverage is expected to exceed 80 percent in 2020.

Progress in the reform of the medical and healthcare system

Xi also visited the Shaxian General Hospital in Sanming City to learn about the local medical and healthcare system's reform.

Shaxian General Hospital has jurisdiction over 12 grass-roots branch hospitals and 128 extended village health clinics. Its establishment is also one of the measures to reform the local medical and health system.

Xi has paid close attention to the country's medical reform progress, and praised Sanming's medical advancement at several key meetings.

At the 33rd meeting of the central leading group for deepening overall reform on March 24, 2017, Xi hailed Sanming's experience in medical reform. He said Sanming's medical reform is in the right direction and has produced obvious results, urging promotion of Sanming's practice nationwide.

Shaxian snacks and rural revitalization

Xi has put forward ardent hopes for the development of Shaxian snacks many times, and on Tuesday, he visited the Yubang Village, which is famous for Shaxian snacks, to inspect work on promoting rural revitalization there.

Hailing from Shaxian, popular restaurant chain Shaxian Snacks is renowned for its pork wontons, peanut sauce noodles, and over 100 other local-flavor delicacies.

Starting with a single booth in a street market, the chain now has more than 88,000 chain stores in China and 62 other countries and regions, pulling in a hefty revenue exceeding 50 billion yuan ($7.6 billion).

Thus far, the Shaxian Snacks trademark has been approved by eight countries: Japan, New Zealand, Malaysia, Indonesia, the Philippines, South Korea, Singapore, and Australia. The Shaxian Snacks stores entered 62 countries, including the U.S., Germany, and Portugal. In three hours, the first store in New York sold out and sales revenue of the first store in Tokyo reached nearly $2,000 in 5 hours. After dominating China, it's now aiming at a bigger market and a brighter future.

https://news.cgtn.com/news/2021-03-23/Xi-Jinping-inspects-Shaxian-County-in-Fujian-Province-YS2YqEdq36/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye